Uridine-Elevating Adjuvant for Radiation-Induced Mucositis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Mucositis, a painful and potentially life-threatening complication of radiation therapy, significantly impacts cancer patients by causing severe discomfort, disrupting treatment, and increasing the risk of infection, particularly in oral and gastrointestinal mucosal tissues.
Innovation Solution
Administering a radiation toxicity-reducing adjuvant, such as 2,2′-anhydropyrimidine or its derivatives, to mitigate the effects of radiation-induced mucositis by inhibiting uridine phosphorylase and elevating uridine levels, thereby protecting mucosal tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If radiation therapy is administered to treat cancer, then cancer cells are destroyed, but mucosal tissues are damaged causing mucositis
Solution Approach 1:
The patent introduces an adjuvant compound as an intermediary substance that selectively protects normal mucosal tissues from radiation damage while allowing cancer cells to be destroyed. The adjuvant acts as a mediator between the radiation therapy and normal tissues, reducing the harmful effects on mucosa without compromising the anti-cancer efficacy.
Solution Approach 2:
The patent changes the chemical and biological parameters of normal tissues by administering the adjuvant compound, which modifies the tissue composition and radiation sensitivity. This parameter change allows normal mucosal tissues to become more resistant to radiation-induced damage while maintaining the ability of radiation to kill cancer cells.
2Reliability
If higher doses of radiation are administered to improve treatment efficacy, then cancer treatment effectiveness increases, but mucositis severity increases
Solution Approach 1:
The adjuvant compound serves as a protective intermediary that enables the administration of higher radiation doses by shielding normal mucosal tissues from excessive damage. This mediator allows the system to operate at higher intensity levels without proportionally increasing the harmful effects on normal tissues.
Solution Approach 2:
The adjuvant is administered before radiation therapy to provide preemptive protection to mucosal tissues. This prior cushioning prepares the normal tissues to withstand the intended high-dose radiation treatment, reducing the severity of mucositis that would otherwise result from such intensive therapy.
3Ease of operation
If radiation therapy is interrupted due to severe mucositis, then patient quality of life improves temporarily, but cancer treatment effectiveness decreases
Solution Approach 1:
The adjuvant is administered in advance of radiation therapy to prevent the development of severe mucositis. This preliminary protective action ensures that patients can tolerate the full course of treatment without experiencing debilitating side effects that would force treatment interruption, thereby maintaining both quality of life and treatment effectiveness throughout the therapy course.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The adjuvant effectively reduces mucositis symptoms, preserves mucosal integrity, and decreases the risk of infection, allowing patients to continue treatment without hospitalization and improving their quality of life.
Implementation Method 1
Administering a radiation toxicity-reducing adjuvant, such as 2,2′-anhydropyrimidine or its derivatives, to mitigate the effects of radiation-induced mucositis by inhibiting uridine phosphorylase and elevating uridine levels
Data Source
AI summary
Methods for reducing radiation therapy induced toxicity, e.g., mucositis, in a subject are provided. Aspects of the methods include administering an effective amount of a radiation toxicity-reducing adjuvant to the subject. In certain embodiments, the radiation toxicity-reducing adjuvant is a 2,2′-anhydropyrimidine, or a derivative thereof. Also provided are compositions for use in practicing the subject methods. The subject methods and compositions find use in a variety of different applications, including the treatment of a variety of different disease conditions.